跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 6,126 条关于
“Focal Segmental Glomerulosclerosis”
全部
6,126
临床试验
5,650
药物
28
机构
19
资讯
429
去年
FDA Accepts Sparsentan sNDA for Full Approval in Focal Segmental Glomerulosclerosis
10个月前
Processa Pharmaceuticals to Present Adaptive Phase 2/3 Study of PCS499 for Rare Kidney Disease FSGS at ASN Kidney Week 2025
去年
Alebund Pharmaceuticals Completes Series C Financing of RMB 550 Million
去年
FILSPARI (sparsentan) Shows Clinical Benefit in IgAN and FSGS, Travere Therapeutics Reports
2年前
Novartis's Atrasentan Shows Promise with Projected $229M Revenue by 2033 for Kidney Diseases
去年
FDA Authorizes Emergency Compassionate Use of VAR 200 for Ultra-Rare ApoCII Amyloidosis
去年
Dimerix's ACTION3 Phase 3 Trial for FSGS Receives Positive IDMC Review
去年
Everest Medicines Reports Promising Phase 1b/2a Results for EVER001 BTK Inhibitor in Primary Membranous Nephropathy
去年
Sparsentan Demonstrates Efficacy in Treating Genetic FSGS, DUPLEX Trial Analysis Shows
11个月前
Dimerix's DMX-200 Receives Orphan Drug Designation in Japan for Rare Kidney Disease Treatment
第 1 页，共 43 页
上一页
下一页
